QIAGEN OmicSoft and Biomedical Knowledge Base

Checkpoint inhibitor and immuno-oncology investigation through OmicSoft Lands APIs

94 views
July 25, 2024
While there is great interest in the scientific community to investigate drug targets and biomarkers from public immune-oncology data, such investigation is hindered by the difficulty in finding and combining related datasets to perform large-scale meta-analyses. This webinar will focus on how high quality curated genomic repositories such as the QIAGEN OmicSoft Lands database immediately allows in-depth investigations across diverse data-sources (GEO, CPTAC, TCGA, GTEx and many more) to discover and validate candidate checkpoint inhibitor drug targets and biomarker investigation.

In this webinar you will learn how to:

• Easily identify relevant samples using extensive manually curated clinical metadata
• Visualize and identify checkpoint inhibition biology related drug target and biomarkers expression patterns in bulk and single cell RNA-seq studies.
• Reveal how the expression of a group of biomarkers (or genes/proteins of interest) correlates in normal and disease tissue

Related videos

QIAGEN OmicSoft and Biomedical Knowledge Base

Knowledge graphs and more: Analytics-driven drug discovery using advanced biomedical...

1,989 views July 19, 2022

High-quality biomedical relationships knowledge is the cornerstone of modern...

QIAGEN OmicSoft and Biomedical Knowledge Base

Supercharge your AI in drug discovery with high-quality biomedical data

660 views October 11, 2023

If you’re working in pharma or biotech, you likely rely on artificial...

QIAGEN OmicSoft and Biomedical Knowledge Base

Unlocking the power of API-based 'omics queries

591 views June 12, 2023

If you're a data scientist or bioinformatician working in biopharma, here's...

QIAGEN OmicSoft and Biomedical Knowledge Base

Integrating deeply curated omics data with APIs for biomarkers and drug-target investigation

482 views September 19, 2023

If you’re a data scientist or bioinformatician working in biopharma and need...